Medroxyprogesterone vs Topiramate: side-by-side comparison
Medroxyprogesterone (Progestin) and Topiramate (Antiepileptic (sulfamate-substituted monosaccharide)) belong to different therapeutic classes and are rarely substitutes for each other. The comparison is useful when a single patient is weighing both options for adjacent or overlapping needs.
| Property | Medroxyprogesterone | Topiramate |
|---|---|---|
| Therapeutic class | Progestin | Antiepileptic (sulfamate-substituted monosaccharide) |
| CAS | 520-85-4 | 97240-79-4 |
| ATC | G03DA02 | N03AX11 |
| Molecular weight | 344.49 g/mol | 339.36 g/mol |
| Brands with this active ingredient | 1 | 1 |
What they share
Medroxyprogesterone and Topiramate share the common regulatory framework for prescription active ingredients, bioequivalence standards for generics, and pharmacist oversight. Beyond that, points in common are limited.
Key differences
Medroxyprogesterone acts by a different mechanism than Topiramate, with indications that barely overlap. Comparing the two is useful when a clinician has mentioned both in the same context or the patient wants to understand why one was prescribed instead of the other.
Mechanisms compared
Medroxyprogesterone: MPA binds progesterone receptors and produces strong progestational effects: thickening cervical mucus, inhibiting ovulation, thinning the endometrium and reducing hot flashes. Topiramate: Topiramate is a sulfamate-substituted monosaccharide with multiple mechanisms of action: blockade of voltage-gated sodium channels, enhancement of gamma-aminobutyric acid (GABA) activity at non-benzodiazepine GABA-A rece…
Indications compared
Medroxyprogesterone: MPA is approved for amenorrhoea, abnormal uterine bleeding due to hormonal imbalance, prevention of endometrial hyperplasia in postmenopausal women receiving estrogen, and prevention of pregnancy (depot formulation). Topiramate: Topiramate is approved in adults and children for the treatment of partial-onset seizures, primary generalised tonic-clonic seizures and seizures associated with Lennox-Gastaut syndrome (as adjunctive or monotherapy depe…
Safety profile
Medroxyprogesterone: Common adverse effects of oral MPA include irregular bleeding, breast tenderness, mood changes, fluid retention and weight gain. Topiramate: Common adverse effects include paraesthesia, fatigue, dizziness, anorexia and weight loss, and cognitive symptoms (word-finding difficulties, concentration problems).
Frequently asked questions
Is Medroxyprogesterone better than Topiramate? ▾
Medroxyprogesterone and Topiramate are not "better or worse" — they treat different things. The sensible question is which fits your specific need.
Can Medroxyprogesterone and Topiramate be combined? ▾
Whether they can be combined depends on the indications and the interaction profile of each. If both are in a single prescription, the prescriber has weighed it; in self-medication they should never be combined.
Do they have the same side-effect profile? ▾
No — they belong to different classes and have distinct side-effect profiles. Each has its own prescribing information.
Products with Medroxyprogesterone
Products with Topiramate
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.